Skip to main content

Publications from the Nanotechnology Characterization Lab

Recent Publications 

Immunophenotyping: analytical approaches and role in preclinical development of nanomedicines.
Newton HS, Dobrovolskaia MA.
Adv Drug Deliv Rev. 2022, 114281. PMID: 35405297.

Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines.
Szebeni J, Storm G, Ljubimova JY, Castells M, Phillips EJ, Turjeman K, Barenholz Y, Crommelin DJA, Dobrovolskaia MA.
Nat Nanotechnol. 2022, 337-346.  PMID: 35393599. Click here to access the full text in view-only mode  https://rdcu.be/cKSA7

Anhydrous Nucleic Acid Nanoparticles for Storage and Handling at Broad Range of Temperatures.
Tran, A.N., Chandler, M., Halman, J., Beasock, D., Fessler, A., McKeough, R.Q., Lam, P.A., Furr, D.P., Wang, J., Cedrone, E., Dobrovolskaia, M.A., Dokholyan, N.V., Trammell, S.R., and Afonin, K.A.
Small. 2022, e2104814. PMID: 35128787.

To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.
Shi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J.Y., Afonin, K.A., and Dobrovolskaia, M.A.
Adv Drug Deliv Rev. 2022, 180, 114079. PMID: 34902516.

Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation.
Afonin, K.A., Dobrovolskaia, M.A., Ke, W., Grodzinski, P., and Bathe, M.
Adv Drug Deliv Rev. 2022, 181, 114081. PMID: 34915069.

 

To see a more comprehensive list of NCL publications, visit our bibliography page on Publons.

 

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Publications from the Nanotechnology Characterization Lab was originally published by the National Cancer Institute.”